Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
P/E ratio for Novavax, Inc. (NVAX)
P/E ratio as of 2023: -0.89
According to Novavax, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.89. At the end of 2022 the company had a P/E ratio of -1.22.
P/E ratio history for Novavax, Inc. from 1996 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -0.89 |
| 2022 | -1.22 |
| 2021 | -6.10 |
| 2020 | -15.01 |
| 2019 | -0.74 |
| 2018 | -3.68 |
| 2017 | -1.97 |
| 2016 | -1.22 |
| 2015 | -14.02 |
| 2014 | -16.15 |
| 2013 | -16.71 |
| 2012 | -8.73 |
| 2011 | -7.39 |
| 2010 | -7.13 |
| 2009 | -5.93 |
| 2008 | -3.57 |
| 2007 | -5.85 |
| 2006 | -10.43 |
| 2005 | -14.73 |
| 2004 | -4.64 |
| 2003 | -10.37 |
| 2002 | -2.80 |
| 2001 | -32.80 |
| 2000 | -13.26 |
| 1999 | -18.14 |
| 1998 | -5.02 |
| 1997 | -12.96 |
| 1996 | -6.33 |